Ірина Давиденко

2.6k citations

33 papers · 1.6k indexed · 1 hit paper · h-index 16

Otorhinolaryngology top 2%
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 5
Oncology top 5%
- Colorectal Cancer Treatments and Studies 11
- Pancreatic and Hepatic Oncology Research 7
- Cancer Treatment and Pharmacology 4
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 9
- Gastric Cancer Management and Outcomes 6
Biological Psychiatry top 10%
Biotechnology
- Cancer Research and Treatments 4
Reproductive Medicine
- Ovarian cancer diagnosis and treatment 4

Co-authors: Kelly S. Oliner Leonard B. Saltz Jennifer J. Knox Thomas W. T. Leung Philip J. Johnson J. Lacava Marinela Capanu Ghassan K. Abou‐Alfa
Cited by: Otorhinolaryngology Hepatology Oncology
Journals: Journal of Clinical Oncology (11 papers)Annals of Oncology (8 papers)European Journal of Cancer (4 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Ірина Давиденко

29 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Ірина Давиденко

Since Specialization

Citations

This map shows the geographic impact of Ірина Давиденко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ірина Давиденко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ірина Давиденко more than expected).

Fields of papers citing papers by Ірина Давиденко

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ірина Давиденко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ірина Давиденко. The network helps show where Ірина Давиденко may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ірина Давиденко, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ірина Давиденко Line = papers co-authored together Ірина Давиденко links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer Gynecologic Oncology ·Rebecca Kristeleit,Ірина Давиденко,Vadim Shirinkin,由理石丸,Igor Bondarenko,Michael J. Goodheart,В. А. Горбунова,C A Penning,Jack Shi,Xiangdong Liu,Robert Newton,Yufan Zhao,Janet Maleski,Lance Leopold,Russell J. Schilder	2017	78
2	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study International Journal of Gynecological Cancer ·Amit M. Oza,Frédèric Selle,Ірина Давиденко,Jacob Korach,César Mendiola,Patricia Pautier,Ewa Chmielowska,Aristotelis Bamias,Andrea DeCensi,Zanete Zvirbule,Antonio González-Martı́n,Roberto Hegg,Florence Joly,Claudio Zamagni,Angiolo Gadducci,Nicolas Martin,Stephen Robb,Nicoletta Colombo	2016	55
3	Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy Annals of Oncology ·Kimberly Blackwell,Vladimir Semiglazov,Agasiian Al,Ірина Давиденко,E. Celani,Roumen Nakov,G. Stiegler,Pritibha Singh,P. García González,Simon Krämer,Nadia Harbeck	2015	65
4	Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. Journal of Clinical Oncology ·David Cunningham,Niall C. Tebbutt,Ірина Давиденко,André M. Murad,Salah‐Eddin Al‐Batran,David H. Ilson,Sergei Tjulandin,Evgeny Gotovkin,Bogusława Karaszewska,Igor Bondarenko,Mohamedtaki Abdulaziz Tejani,Anghel Adrian Udrea,Mustapha Tehfé,Nigel Baker,Kelly S. Oliner,Yilong Zhang,Tien Hoang,Roger Sidhu,Daniel Virgil Thomas Catenacci	2015	120
5	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer Clinical Cancer Research ·Eric Van Cutsem,Cathy Eng,Elżbieta Nowara,Anna Świeboda-Sadlej,Niall C. Tebbutt,Edith P. Mitchell,Ірина Давиденко,Joe Stephenson,Élena Elez,Hans Prenen,Hongjie Deng,Rui Tang,Ian McCaffery,Kelly S. Oliner,Lisa Chen,Jennifer Gansert,Elwyn Loh,Dominic Smethurst,Josep Tabernero	2014	92
6	Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma Annals of Oncology ·David Propper,Ірина Давиденко,John Bridgewater,Limas Kupčinskas,A. Fittipaldo,Carina Hillenbach,Barbara Klughammer,Michel Ducreux	2014	25
7	A Randomized, Placebo-Controlled, Phase 2 Study of Efatutazone Maintenance Therapy in Patients with Advanced Colorectal Cancer Who Have Achieved Disease Control Following First-Line Chemotherapy Annals of Oncology ·Éveline Boucher,Ірина Давиденко,D. Hadler,Reinhard von Roemeling,Giuseppe Aprile	2014	2
8	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study The Lancet Oncology ·Timothy Iveson,Ross C. Donehower,Ірина Давиденко,S. Tjulandin,Andrzej Deptała,Mark Harrison,藤井文武,K C Lakshmaiah,Anne Thomas,Yizhou Jiang,Min Zhu,Rui Tang,Abraham Anderson,Sarita Dubey,Kelly S. Oliner,Elwyn Loh	2014	216
9	Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma Annals of Oncology ·David Cunningham,S-E. Al-Batran,Ірина Давиденко,David H. Ilson,Serie Rav,Niall C. Tebbutt,Nigel Baker,Rajul K. Jain,Tien Hoang	2014	8
10	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial Clinical Cancer Research ·Josep Tabernero,Rocio García‐Carbonero,James T. Cassidy,Alberto Sobrero,Eric Van Cutsem,Claus-Henning Köhne,Sabine Tejpar,Oleg Gladkov,Ірина Давиденко,Ramón Salazar,Hana Oh,Sergey Cheporov,Olga Burdaeva,Fernando Rivera,Leslie Samuel,正人牛島,Vanessa Potter,M. L. Lapidus,Nathalie A. Lokker,Peter J. O’Dwyer	2013	69
11	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialbreakdown → The Lancet Oncology ·Jan B. Vermorken,Won Woong Lee,Ірина Давиденко,Lisa Licitra,Eric Winquist,Cristian Villanueva,Paolo Foa,Sylvie Rottey,Krzysztof Składowski,Makoto Tahara,Vasant R. Pai,Sandrine Faivre,C. Blajman,Arlene A. Forastiere,B. Stein,Kelly S. Oliner,Zhiying Pan,Bruce Allen Bach	2013	314
12	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma Ghassan K. Abou‐Alfa,Philip J. Johnson,Jennifer J. Knox,Marinela Capanu,Ірина Давиденко,J. Lacava,Thomas W. T. Leung,Leonard B. Saltz	2013	12
13	RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Journal of Clinical Oncology ·David Cunningham,Salah‐Eddin Al‐Batran,Ірина Давиденко,David H. Ilson,André M. Murad,Niall C. Tebbutt,Yizhou Jiang,Elwyn Loh,Sarita Dubey,(unknown)	2013	17
14	Klinicheskie rekomendatsii po profilaktikei lecheniyu toshnoty i rvoty u bol'nykh,poluchayushchikh khimio- i luchevuyuprotivoopukholevuyu terapiyu SHILAP Revista de lepidopterología ·I V Poddubnaya,Mikhail Lichinitser,Ahmed Rufai Isah,I. Kostyukov,江山,Kai-Yuan Cheng,Aishwarya Rao Nagar,Л. В. Болотина,正人牛島,Oleg Gladkov,Ірина Давиденко,Lyudmila Zhukova,И. А. Королева,Patrik Macho,George Manikhas,Nara Hiroki,Anne Balsamo,Р. Ш. Хасанов,M. Sierra	2011	1
15	PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) Annals of Oncology ·Cathy Eng,Elżbieta Nowara,Anna Świeboda-Sadlej,Niall C. Tebbutt,Edith Mitchell,Ірина Давиденко,Élena Elez,Kelly S. Oliner,Lisa Chen,Jing Huang,Ian McCaffery,Elwyn Loh,Dominic Smethurst,Eric Van Cutsem	2011	0
16	A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy. Journal of Clinical Oncology ·Tone Ikdahl,Ірина Давиденко,Claudio Bassi,E V Sorokina,L Smith,Sue Anne McLachlan,Steven J.M. Jones,Mitch Raponi,Jeffrey D. Isaacson,Peter Forensyah,Lindsey Rolfe,Yasin Özyürek,Elizabeth Poplin	2011	4
17	A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. Journal of Clinical Oncology ·Cathy Eng,Eric Van Cutsem,Elżbieta Nowara,Anna Świeboda-Sadlej,Niall C. Tebbutt,Edith P. Mitchell,Ірина Давиденко,Kelly S. Oliner,篤高橋,Jing Huang,Ian McCaffery,Elwyn Loh,Dominic Smethurst,Josep Tabernero	2011	31
18	6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma European Journal of Cancer ·Timothy Iveson,Ross C. Donehower,Ірина Давиденко,S. Tjulandin,Lucia Koch De B.,Shanil Govindpersad,Elwyn Loh,Daniela Antonia Francisco,Kelly S. Oliner,Chen Tai-zhong	2011	23
19	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma JAMA ·Ghassan K. Abou‐Alfa,Philip J. Johnson,Jennifer J. Knox,Marinela Capanu,Ірина Давиденко,J. Lacava,Thomas W. T. Leung,Bolorsukh Gansukh,Leonard B. Saltz	2010	343
20	8514 SPECTRUM, a phase III trial for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab: interim pooled safety analysis European Journal of Cancer Supplements ·Jessica R. Richmond,Ірина Давиденко,Eric Winquist,Lisa Licitra,Krzysztof Składowski,T-E. Ciuleanu,Rakesh Kumar,P. Foa,Jennifer Gansert,Jan B. Vermorken	2009	0

About Ірина Давиденко

Ірина Давиденко is a scholar working on Hepatology, Otorhinolaryngology and Anatomy, having authored 33 papers that have together received 1.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (9 papers), Pancreatic and Hepatic Oncology Research (7 papers), Gastric Cancer Management and Outcomes (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Cancer Research and Treatments (4 papers), Cancer Treatment and Pharmacology (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). The work is most often cited by research in Otorhinolaryngology (242 citations), Hepatology (432 citations) and Oncology (807 citations). Ірина Давиденко has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Kelly S. Oliner, Leonard B. Saltz, Jennifer J. Knox, Thomas W. T. Leung, Philip J. Johnson, J. Lacava, Marinela Capanu, Ghassan K. Abou‐Alfa, Bolorsukh Gansukh and Elwyn Loh. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Clinical Cancer Research and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact